Blow-Fill-Seal
Blow-fill-seal (BFS) forms a plastic container from resin, fills it with sterile product, and seals it — all within a few seconds, inside a single machine, with the container never existing as an open vessel exposed to the room environment before it is sealed. That design fundamentally changes the risk profile compared with conventional vial filling, and regulators have increasingly recognized BFS as an advanced aseptic technology deserving of a distinct evaluation approach.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 19 LINKSBlow-fill-seal changes the risk profile rather than the requirement: the container never exists as an open vessel in the room, so the contamination controls that matter move to the machine, the shroud air and the resin.
06 · QUALITY MATURITY — BLOW-FILL-SEAL, REACTIVE TO ADAPTIVE
The line is qualified as though it were conventional filling, and machine stops are handled by operator judgement.
BFS-specific parameters are recorded and media fills are performed, but the simulation does not reproduce campaign duration or machine-stop recovery.
Media fills reflect real campaign length and the interventions a stop actually requires; shroud air quality and formed-container integrity are monitored in production.
Parameter and container integrity data are trended across campaigns so mould, parison or resin drift is caught before a batch is affected.
Container, resin and machine parameters are developed together, and the process runs long campaigns with human contact designed out rather than procedurally limited.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 4 regulatory bodies: FDA, EMA, ASTM, ISPE.
RECORDS & OBJECTIVE EVIDENCE
- Machine parameter records for parison, mould and fill, at the batch level
- Air and particulate quality inside the shroud during production
- Media fill design covering campaign duration and machine-stop recovery
- Container closure integrity data on containers formed by this process
- Resin supplier qualification, including extractables and leachables assessment
COMMON INSPECTION FINDINGS
- A media fill shorter than, or otherwise unrepresentative of, a routine campaign
- Interventions following a machine stop that were never simulated
- Container closure integrity demonstrated at development only, with no routine confirmation
- Shroud air quality not monitored while the machine is running
- A resin or supplier change treated as like-for-like without assessment
How the process differs from conventional filling
In a conventional aseptic line, a pre-formed, pre-sterilized container is presented open to the classified environment for the entire filling and stoppering sequence; in BFS, the container does not exist until moments before it is filled and sealed, and the interval during which the product could theoretically be exposed to the environment is measured in seconds rather than the minutes the conventional process requires. This is the central reason regulators treat BFS as capable of a materially lower contamination risk profile than open-vial filling, when the equipment and process are properly designed and controlled.
The extrusion, forming, and filling sequence
Molten plastic resin is extruded into a tube (the parison), a mold closes around it and blows it into the container shape using sterile-filtered air, the fill nozzle then dispenses the sterile product into the freshly formed container, and the mold closes again to seal it — the whole sequence happens inside the machine’s own shrouded, HEPA-filtered environment, which is itself treated as the critical zone rather than the room air around the machine.
Contamination control specific to BFS
Even with the shortened open-container interval, BFS carries its own specific risks that a conventional line does not: the extrusion process itself operates at high temperature, the parison-cutting mechanism and mold-closing action are potential particle-generation points, and the sterile air used to blow-form the container has to be validated as a product-contact utility in its own right. Annex 1 (2022) explicitly recognizes BFS as an advanced aseptic technology and expects its contamination control strategy to address these process-specific risks rather than simply defaulting to conventional-line controls.
Where BFS is and is not a fit
BFS is well suited to high-volume, single-dose or unit-dose liquid products — respiratory inhalation solutions, ophthalmics, and certain parenteral products — where the plastic container material and the process’s thermal exposure are compatible with the formulation; it is not a universal replacement for glass vial filling, and material compatibility, extractables from the resin, and the product’s heat sensitivity during the brief extrusion/forming step all have to be evaluated for each formulation.
FREQUENTLY ASKED
Why is BFS generally considered lower contamination risk than conventional vial filling?
The plastic container is formed, filled, and sealed within the same machine cycle, so it never exists as an open vessel exposed to the surrounding room air for more than a few seconds — compared with the extended open-container interval typical of conventional filling and stoppering on a traditional aseptic line.
Does BFS eliminate the need for a contamination control strategy?
No — Annex 1 explicitly addresses BFS as an advanced aseptic technology with its own specific risks (high extrusion temperatures, mold-closing particle generation, the sterile air used to form the container) that the site’s contamination control strategy has to evaluate on their own terms, not simply inherit from conventional-line controls.
What kinds of products are typically manufactured by blow-fill-seal?
BFS is commonly used for high-volume, single-dose liquid products such as respiratory inhalation solutions and ophthalmic preparations, where the plastic container material and the product’s tolerance for brief thermal exposure during container formation are compatible with the formulation.